araag2/HINT huggingface dataset:
Clinical trial NCT00160563 (phase 3, status: terminated)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: levocetirizine
SMILES: OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Reason stopped: 
    the predecessor study a00309 (nct00152464) did not show statistical significance in time to
    onset of asthma between the levocetirizine and placebo groups.
  
Eligibility criteria:

        Inclusion Criteria:

        Inclusion criteria which must be verified at the end of first 18-months treatment (Visit 9)

          -  Having completed the previous 18-month treatment period of the EPAAC trial -
             NCT00152464

        Exclusion Criteria:

          -  None
Clinical trial NCT00679484 (phase 3, status: terminated)
Conditions: chronic heart failure, high blood b-type (or brain) natriuretic peptide (bnp) level
ICD codes: I50.812, I50.22, I50.32, I50.813, I50.23, I50.33, I50.42
Drugs: olmesartan medoxomil + candesartan cilexetil placebo, olmesartan medoxomil placebo + candesartan cilexetil
SMILES: CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O
Reason stopped: 
    lack of subject recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, adult, out-patients aged between 18 and 85 years

          -  Patients with documented hospital admission within the previous 3 months before
             randomization with discharge diagnosis of CHF

          -  Patients with functional NYHA class II-IV with LVEF < 40% assessed within the last 3
             months

          -  Patients with blood BNP levels > 400 pg/ml or NT-ProBNP levels > 1500 pg/ml

          -  Patients with CHF due to ischemic heart disease, idiopathic dilated cardiomyopathy
             (IDC), mitral or aortic insufficiency or hypertension

          -  Patients with stable conventional treatment with diuretics, ACEI and/or beta-blockers
             and/or aldosterone antagonists for at least 2 months prior to randomisation, unless
             documented contraindication or intolerance

        Exclusion Criteria:

          -  Females who are pregnant or plan a pregnancy during the time of the trial, are nursing
             or are of childbearing potential and not using acceptable methods of contraception. If
             a female becomes pregnant during the study, she has to be withdrawn immediately

          -  Patients with current hospitalisation due to heart failure

          -  Patients with stroke or transient ischemic attack (TIA) within the last 3 months

          -  Patients with acute coronary syndrome, myocardial infarction, coronary artery bypass
             or angioplasty within 3 months

          -  Planned cardiac surgery, revascularization or resynchronization within the study
             period

          -  Patients with operable valvular disease or significant obstructive cardiomyopathy

          -  Patients with bradycardia [heart rate (HR) < 50 bpm]

          -  Patients with hypotension [systolic blood pressure (SBP) < 90 mmHg]

          -  Patients with obstructive pneumopathy

          -  Patients with clinical significant renal failure (creatininemia > 200 micromol/l)
Clinical trial NCT01057407 (phase 3, status: completed)
Conditions: chronic kidney disease, renal dialysis, renal insufficiency
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0, Z99.2, Z91.15, N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: asp1585, sevelamer hydrochloride
SMILES: NCC=C.ClCC1CO1
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic kidney disease patients on hemodialysis

          -  Hyperphosphatemia

          -  Patients on a phosphate binder or phosphate lowering drug for 28 days or longer, and
             that, those for whom the dose has not been changed within 28 days

          -  Written informed consent

        Exclusion Criteria:

          -  Patients with gastrointestinal surgery or enterectomy

          -  Patients with severe cardiac diseases

          -  Patients with severe constipation or diarrhea

          -  Patients with a history or complication of malignant tumors

          -  Patients with uncontrolled hypertension

          -  Patients treated with parathyroid intervention
Clinical trial NCT00423813 (phase 3, status: completed)
Conditions: fibromyalgia
ICD codes: M79.7
Drugs: placebo, xyrem®
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [Na+].OCCCC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects, 18 years or older who meet the American College of
             Rheumatology (ACR) diagnostic criteria for fibromyalgia.

        Exclusion Criteria:

          -  Subjects will be excluded if they have a history of rheumatic disease or other
             disorders that may compromise reliable representation of subjective symptoms.

          -  Any other condition that will cause a risk to subjects if they participate in the
             trial is also a reason for exclusion.
Clinical trial NCT00237653 (phase 3, status: terminated)
Conditions: cytomegalovirus infections, inflammatory bowel diseases
ICD codes: P35.1, M06.4, G61.89, G61.9, M35.81, G61.81, K75.9, M27.2
Drugs: valganciclovir
SMILES: CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O
Reason stopped: 
    difficulty to include patients
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patient suffering from Crohn's disease, ulcerative colitis, unclassifiable colitis or
             pouchitis.

          -  Disease needing to be treated by corticoids and/or immunosuppressive drugs.

          -  Infection by cytomegalovirus.

          -  New attack during the three previous months.

        Exclusion Criteria:

          -  Serious or complicated attack, needing to be operated.

          -  Patient suffering from a psychiatric disease or is uncooperative.

          -  Patient suffering from another serious disease.

          -  Patient already participating in another clinical trial.